PCSK9 Inhibitor

PHILADELPHIA — LDL is a central component of CV risk reduction and data now show clear benefits of a sustained and substantial reduction, even in the setting of very high baseline LDL, according to a speaker.

The U.S. Supreme Court unanimously ruled in favor of Regeneron and Sanofi that two of Amgen’s patents for PCSK9 inhibitor technology were invalid, allowing alirocumab to stay on the U.S. market.

Healio and Cardiology Today have aggregated the top cardiology headlines of March 2023.

In the past decade, there have been major advances in lipid-lowering therapeutics, and another was made apparent in March at the American College of Cardiology Scientific Session.

NEW ORLEANS — In a phase 2 trial, an oral PCSK9 inhibitor lowered LDL about the same amount observed with injectable PCSK9 inhibitors for 8 weeks, researchers reported at the American College of Cardiology Scientific Session.